MV
Therapeutic Areas
Erasca Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ERAS-007 | Advanced solid tumors with RAS/MAPK pathway alterations | Phase 1b/2 |
| ERAS-601 | Advanced solid tumors with RAS/MAPK pathway alterations | Phase 1b/2 |
| ERAS-3490 | KRAS G12C-mutated NSCLC (including CNS metastases) | Phase 1 |
| ERAS-0015 | Advanced solid tumors with RAS mutations | Preclinical |
| ERAS-801 | EGFR-altered glioblastoma | Phase 1 |
| ERAS-013 | Advanced solid tumors with RAS/MAPK pathway alterations | Preclinical |
| ERAS-113 | Undisclosed solid tumors | Discovery |
Leadership Team at Erasca
JE
Jonathan E. Lim, M.D.
Chairman, CEO and Co-founder
DC
David Chacko, M.D.
Chief Financial Officer and Chief Business Officer
NC
Nik Chetwyn, Ph.D.
Chief Operating Officer
EG
Ebun Garner, J.D.
Chief Legal Officer
CL
Chandra Lovejoy
Chief Regulatory Affairs Officer
SM
Shannon Morris, M.D., Ph.D.
Chief Medical Officer
RS
Robert Shoemaker, Ph.D.
Chief Scientific Officer
LT
Lisa Tesvich-Bonora, Ph.D.
Chief People Officer
BB
Brian Baker, CPA
Senior Vice President of Finance
LB
Les Brail, Ph.D.
Senior Vice President of Early Clinical Development